Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSK-mannitol is a generic intravenous formulation of mannitol, a small molecule sugar alcohol that functions as an osmotic diuretic. Developed by Puniska Healthcare (now a subsidiary of Amneal Pharmaceuticals), it is primarily used to reduce elevated intracranial pressure and treat cerebral edema by drawing fluid out of tissues through osmotic pressure. Additionally, it is indicated for the promotion of diuresis in the prevention or treatment of the oliguric phase of acute renal failure and for the reduction of high intraocular pressure. As an osmotic agent, mannitol is not significantly metabolized and is filtered by the glomeruli without substantial tubular reabsorption, thereby increasing the osmotic pressure of the glomerular filtrate and hindering water reabsorption in the kidneys.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mannitol.